Results 11 to 20 of about 3,844,628 (256)
Livers, 2021 Chronic hepatitis C virus infection is still one of the major risk factors for the development of hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer.
Zuzana Macek Jilkova +3 more
doaj +2 more sources
Bulletin of the National Research Centre, 2018 Background Chronic hepatitis C virus (HCV) infection represents a global public health challenge, and new drugs have been authorized for its treatment. The current study aimed to detect the change in blood levels of tryptophan and phenylalanine with the ...
Eman G. Behiry +5 more
doaj +2 more sources
IDCases, 2018 The newer oral treatments for chronic hepatitis C virus infection are one of the greatest revolutions in modern medicine. These drugs promise to eradicate the infection, showing high cure rates even in difficult to treat populations with very few side ...
Cátia Dias +5 more
doaj +2 more sources
Antiviral resistance and direct-acting antiviral agents for HCV
Antiviral Therapy, 2012 Direct-acting antiviral (DAA) agents specifically target viral proteins. Two DAAs have been already been approved for the treatment of HCV infection and many more are in development.
Beard, M., Aloia, A., Locarnini, S.
core +4 more sources
Biology, 2020 (1) Background: Direct-acting antiviral therapy for chronic hepatitis C virus (HCV) infection is associated with high sustained virologic response (SVR) and overcomes negative predictive factors, including steatosis, in patients without human ...
Leigh P. Johnson, Richard K. Sterling
doaj +2 more sources
Management of Direct‐Acting Antiviral Failures [PDF]
Clinical Liver Disease, 2020 Answer questions and earn CME.
Maryam, Alimirah +2 more
openaire +2 more sources
, 2022 Characteristics of Medicare beneficiaries who initiated direct-acting antiviral agents (DAA), 2014–2017.
Linh Tran (512201) +3 more
core +1 more source
Direct-acting antivirals for chronic hepatitis C [PDF]
Cochrane Database of Systematic Reviews, 2016 Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response ...
Jakobsen, Janus C. +15 more
openaire +8 more sources
Direct-acting antivirals and visceral leishmaniasis: a case report [PDF]
BMC Infectious Diseases, 2019 Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions of the immune system impair the capability to resolve the infection and allow reactivation from sites of latency
Colomba C. +7 more
openaire +4 more sources
, 2022 Supplemental Material for Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C by Chinyere L Nkwocha, Pamela S Carter, Somer Blair, James M Blackwell and Esther O Fasanmi in Antiviral ...
Esther O Fasanmi (14244768) +4 more
core +1 more source